T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

Drake, C.G., Jaffee, E. & Pardoll, D.M. Mechanisms of immune evasion by tumors. Adv. Immunol.90, 51–81 (2006).

Chen, L. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity. Nat. Rev. Immunol.4, 336–347 (2004).

Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol.6, 295–307 (2006).

Watts, T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol.23, 23–68 (2005).

Riley, J.L. & June, C.H. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood105, 13–21 (2005).

Uno, T. et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med.12, 693–698 (2006).

Daugherty, A.L. & Mrsny, R.J. Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Deliv. Rev.58, 686–706 (2006).

Rabu, C. et al. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J. Biol. Chem.280, 41472–41481 (2005).

Copier, J. & Dalgleish, A. Overview of tumor cell-based vaccines. Int. Rev. Immunol.25, 297–319 (2006).

Townsend, S.E. & Allison, J.P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science259, 368–370 (1993).

Melero, I. et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol.28, 1116–1121 (1998).

Guinn, B.A., DeBenedette, M.A., Watts, T.H. & Berinstein, N.L. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol.162, 5003–5010 (1999).

Yu, P. et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol.5, 141–149 (2004).

Andarini, S. et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res.64, 3281–3287 (2004).

Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med.355, 1018–1028 (2006).

Blansfield, J.A. et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother.28, 593–598 (2005).

Arlen, P.M. et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res.12, 1260–1269 (2006).

Milowsky, M.I. et al. Vascular targeted therapy with anti–prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol.25, 540–547 (2007).

Peggs, K.S. et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet362, 1375–1377 (2003).

Micklethwaite, K. et al. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide–specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.13, 707–714 (2007).

Leen, A.M., Rooney, C.M. & Foster, A.E. Improving T cell therapy for cancer. Annu. Rev. Immunol.25, 243–265 (2007).

Kershaw, M.H., Teng, M.W., Smyth, M.J. & Darcy, P.K. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat. Rev. Immunol.5, 928–940 (2005).

Papanicolaou, G.A. et al. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood102, 2498–2505 (2003).

Gong, M.C. et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia1, 123–127 (1999).

Sadelain, M., Riviere, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer3, 35–45 (2003).

Lamers, C.H. et al. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol. Immunother.56, 1875–1883 (2007).

Brentjens, R.J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med.9, 279–286 (2003).

Gade, T.P. et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res.65, 9080–9088 (2005).

Bromley, S.K. et al. The immunological synapse and CD28–CD80 interactions. Nat. Immunol.2, 1159–1166 (2001).

Pentcheva-Hoang, T., Egen, J.G., Wojnoonski, K. & Allison, J.P. B7–1 and B7–2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity21, 401–413 (2004).

Nam, K.O. et al. Cross-linking of 4-1BB activates TCR-signaling pathways in CD8· T lymphocytes. J. Immunol.174, 1898–1905 (2005).

Radoja, S. et al. CD8+ tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J. Immunol.167, 5042–5051 (2001).

Somersalo, K. et al. Cytotoxic T lymphocytes form an antigen-independent ring junction. J. Clin. Invest.113, 49–57 (2004).

Jang, I.K., Lee, Z.H., Kim, Y.J., Kim, S.H. & Kwon, B.S. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-κB. Biochem. Biophys. Res. Commun.242, 613–620 (1998).

Ding, L. & Shevach, E.M. Activation of CD4· T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation). Eur. J. Immunol.24, 859–866 (1994).

Smythe, J.A. et al. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4· and CD8· T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity. J. Immunol.163, 3239–3249 (1999).

Maus, M.V. et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol.20, 143–148 (2002).

Holdorf, A.D., Lee, K.H., Burack, W.R., Allen, P.M. & Shaw, A.S. Regulation of Lck activity by CD4 and CD28 in the immunological synapse. Nat. Immunol.3, 259–264 (2002).

Tseng, S.Y., Liu, M. & Dustin, M.L. CD80 cytoplasmic domain controls localization of CD28, CTLA-4, and protein kinase Cθ in the immunological synapse. J. Immunol.175, 7829–7836 (2005).

Keller, A.M. et al. Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules. Proc. Natl. Acad. Sci. USA104, 5989–5994 (2007).

Dustin, M.L. Impact of the immunological synapse on T cell signaling. Results Probl. Cell Differ.43, 175–198 (2006).

Stinchcombe, J.C., Majorovits, E., Bossi, G., Fuller, S. & Griffiths, G.M. Centrosome polarization delivers secretory granules to the immunological synapse. Nature443, 462–465 (2006).

Thompson, C.B. & Allison, J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity7, 445–450 (1997).

Butte, M.J., Keir, M.E., Phamduy, T.B., Sharpe, A.H. & Freeman, G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity27, 111–122 (2007).

Finger, E.B. & Bluestone, J.A. When ligand becomes receptor—tolerance via B7 signaling on DCs. Nat. Immunol.3, 1056–1057 (2002).

Sanchez-Lockhart, M. & Miller, J. Engagement of CD28 outside of the immunological synapse results in up-regulation of IL-2 mRNA stability but not IL-2 transcription. J. Immunol.176, 4778–4784 (2006).

Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer5, 263–274 (2005).

Gallardo, H.F., Tan, C. & Sadelain, M. The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Ther.4, 1115–1119 (1997).

Latouche, J.B. & Sadelain, M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat. Biotechnol.18, 405–409 (2000).

Szymczak, A.L. et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide–based retroviral vector. Nat. Biotechnol.22, 589–594 (2004).